Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, open-label phase 2 study in patients with metastatic PC or
BTC refractory or intolerant to at least one line of prior systemic chemotherapy with
gemcitabine or platinum-containing regimens to determine the efficacy and safety of nivolumab
or nivolumab plus ipilimumab administered concurrently with high dose RT. Patients with
metastatic PC or BTC who are feasible candidates for radiation and biopsy of primary and/or
metastatic lesions will be included.